Business UpdateMay 18, 2026, 08:47 AM
Autonomix Medical Abstracts Accepted for EuroPCR 2026
AI Summary
Autonomix Medical, Inc. announced that two abstracts showcasing its innovative transvascular nerve-targeting platform technology have been accepted for presentation at EuroPCR 2026, a leading interventional cardiovascular medicine course. The abstracts, focusing on pain mitigation in pancreatic cancer and precision-guided nerve illumination, highlight increasing clinical and scientific interest in the company's approach. Management emphasized that participation in such premier international forums is crucial for advancing awareness of their platform technology and its broad applicability across various disease states.
Key Highlights
- Two abstracts highlighting Autonomix's transvascular nerve-targeting platform accepted for EuroPCR 2026.
- Abstracts focus on pain mitigation in pancreatic cancer and precision-guided nerve illumination.
- Presentations will take place at EuroPCR 2026 from May 19–22 in Paris, France.
- Acceptance underscores growing clinical and scientific interest in the company's approach.
- Participation aims to advance awareness of the platform's potential across multiple disease states.
- CEO Brad Hauser and CMO Dr. Robert Schwartz highlighted the progress of clinical and scientific efforts.
Price Impact
More from AMIX